Perimeter Medical Imaging AI (TSXV: PINK; OTCQX: PYNKF) has announced that Medical City Dallas Hospital—an award-winning, 899-bed acute care hospital in the Dallas-Fort Worth area—has adopted the company’s current S-Series OCT (optical coherence tomography) technology for high-resolution visualization of tissue microstructures during surgery.
The move follows the hospital’s participation in the pivotal, randomized controlled trial of Perimeter’s next-generation B-Series device, which combines proprietary artificial intelligence (AI) technology with OCT and is currently under FDA evaluation for use during breast-conserving surgeries in the U.S.
In a statement, Adrian Mendes, CEO of Perimeter, commented, “We are incredibly proud to partner with Medical City Dallas Hospital and its team of surgeons, who are truly innovators in their field. Working with Dr. DiPasquale and Dr. Anderson and the Medical City Dallas team, who used our B-Series in the randomized controlled pivotal trial, has been invaluable to advancing our next-generation product and we are pleased that they are adopting our commercially approved S-Series to potentially enhance margin visualization in the OR.”
Medical City Dallas Hospital is the latest U.S. hospital to adopt the S-Series OCT, as Perimeter continues to deploy the technology nationwide. Cleared by the FDA in 2021 for a general tissue indication, S-Series OCT is a high-resolution imaging technology that—unlike X-ray, magnetic resonance imaging (MRI), or ultrasound—can ‘see’ disease at the cellular level. It is optimized to a depth of two millimetres for identifying regions of interest in tissue microstructures, and features such as blood vessels, ducts, and glands, making it ideal for visualizing surgical margins.
